Found 29 articles
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022.
Kymera has raised money through sale of more than 2,769,000 shares of common stock to help support the company's ongoing clinical and preclinical programs.
Amgen Reports Second Quarter 2022 Financial Results
Amgen announced financial results for the second quarter of 2022.
PLEXIUM APPOINTS BRIAN WONG, M.D., PH.D., TO ITS BOARD OF DIRECTORS
Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors.
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
Plexium Appoints Stephen Mullennix as Chief Financial Officer
Plexium, Inc., a leading next-generation targeted protein degradation company, announced the appointment of Stephen Mullennix as Chief Financial Officer.
The alliance will pair AbbVie’s neuroscience capabilities with Plexium’s comprehensive TPD platform.
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022.
AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisiana.
Plexium raised millions for its multi-year research collaboration and license deal with Amgen to identify novel targeted protein degradation therapeutics.
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
Plexium, Inc., a leading next-generation targeted protein degradation company, announced the completion of an oversubscribed $102M financing, led by BVF Partners, L.P. and TCG X, with participation from new investors Softbank Vision Fund 2, RA Capital Management, Surveyor Capital, and Pappas Capital.
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)*.
Much of Amgen's modest gains in the year can be attributed to its manufacturing partnership with Eli Lilly and an increase in sales for EVENITY.
AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING
In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition to full year 2022 guidance.
Amgen Outlines Growth Strategy Through 2030 At Virtual Business Review
Amgen outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with its current portfolio of marketed medicines and with the numerous new medicines it is advancing through its pipeline.
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020.
The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.
AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES
Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets.